Wolfe Research analyst Andy Chen downgraded Vertex Pharmaceuticals (VRTX) to Peer Perform from Outperform.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $621 from $617 at Goldman Sachs
- Vertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank
- Vertex Pharmaceuticals price target raised to $464 from $462 at Morgan Stanley
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Mixed Performance and Future Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue